The main disadvantage of anti-VEGF therapy is attributed to a number of consequences, such as intraocular inflammation, retinal detachment, and ocular hemorrhage occasionally due to the short half-life of the molecules, which require repeated intravitreal injections. The gene discussed is VEGFA; the disease is retinal detachment.